发明名称 METHOD FOR REPAIRING DISORDERS IN CYTOKINE SYSTEM IN PREGNANT WOMEN POSSESSING GESTOSIS ON THE BACKGROUND OF AUTOIMMUNE DISEASES
摘要 medicine. SUBSTANCE: method involves administering plasmapheresis and ultrasonic blood irradiation therapy with physiological salt solution of sodium chloride in the amount of 300-400 ml being infused with Sybasone in the amount of 0.2 mg/kg of body weight and Dimedrol in the amount of 0.2 mg/kg of body weight being added. The session is carried out in two stages. 300-400 ml of blood is taken at the first stage. It is centrifuged at 1600 rpm during 15 min. Plasma compensation is carried out depending on initial hematocrit reading, general protein and blood platelets contents in patient blood. General protein contents being from 60 to 80 g/l, blood platelets from 150 to 250 g/l, hematocrit reading being from 0.32 to 0.36 l/l, plasma compensation is carried out with physiological salt solution of sodium chloride in the amount equal to 2-fold value of removed plasma. General protein contents being from 60 to 80 g/l, blood platelets from 150 to 250 g/l, hematocrit reading being greater than 0.36 l/l, plasma compensation is carried out with colloid solution of rheopolyglycine or rheomacordex or rheogluman and physiological salt solution of sodium chloride in 2:1 proportion in the general amount equal to 2-fold value of removed plasma. General protein contents being less than 60 g/l, blood platelets less than 150 g/l, hematocrit reading being from 0.32 to 0.36 l/l, plasma compensation is carried out with fresh frosted plasma of the same group in the amount of one volume of removed plasma and physiological salt solution of sodium chloride in the amount equal to 2-fold value of removed plasma. General protein contents being less than 60 g/l, blood platelets less than 150 g/l, hematocrit reading being greater than 0.36 l/l, plasma compensation is carried out with fresh frosted plasma of the same group in the amount of one volume of removed plasma and colloid solution of rheopolyglycine or rheomacordex or rheogluman in the amount equal to the volume of removed plasma. Formed blood elements concurrently treated with ultrasonic radiation are reinfused at the second stage. EFFECT: enhanced effectiveness of treatment; reduced adverse side effects caused by drug therapy. 4 cl, 2 tbl
申请公布号 RU2191047(C1) 申请公布日期 2002.10.20
申请号 RU20010117576 申请日期 2001.06.22
申请人 SUDARSTVENNYJ MEDITSINSKIJ UNIVERSITET" SKOGO PROFESSIONAL'NOGO OBRAZOVANIJA "SIBIRSKIJ GO;G UCHREZHDENIE VYSSHEGO I POSL 发明人 MAKHMUTKHODZHAEV A.SH.;KHOLOPOV A.V.;EVTUSHENKO I.D.
分类号 A61N5/08;A61M1/36;A61P15/00;(IPC1-7):A61N5/08 主分类号 A61N5/08
代理机构 代理人
主权项
地址